RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Nanfang Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorNanfang Hospital南方医科大学南方医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07637448, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Patients with histologically or cytologically confirmed, previously untreated EGFR-mutant (19del/L858R) locally advanced or metastatic (stage IIIB/IIIC or IV) non-small cell lung cancer (NSCLC), according to the 9th edition of the TNM staging system for lung cancer jointly issued by the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC);

    Inclusion criterion 1

  3. Prior treatment with anti-PD-1/PD-L1 immunotherapy;

    Exclusion criterion 2

    Receipt of systemic corticosteroids or other immunosuppressive therapy within 2 weeks prior to the first dose of study drug;

    Exclusion criterion 5

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

    Inclusion criterion 4

  5. Patients who are willing to receive third-generation EGFR-TKI targeted therapy, followed by maintenance therapy with a PD-1 antibody during the stable phase of the disease (defined as no further tumor shrinkage for at least two consecutive assessments based on RECIST v1.1 criteria);

    Inclusion criterion 3

  6. At least one measurable or non-measurable but evaluable lesion according to RECIST version 1.1;

    Inclusion criterion 5

  7. Known history of immunodeficiency, or positive test for human immunodeficiency virus (HIV) antibody;

    Exclusion criterion 19

    Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection;

    Exclusion criterion 20

  8. Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study period;

    Exclusion criterion 22

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07637448, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients with histologically or cytologically confirmed, previously untreated EGFR-mutant (19del/L858R) locally advanced or metastatic (stage IIIB/IIIC or IV) non-small cell lung cancer (NSCLC), according to the 9th edition of the TNM staging system for lung cancer jointly issued by the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC);
  • Male or female patients aged ≥ 18 years;
  • Patients who are willing to receive third-generation EGFR-TKI targeted therapy, followed by maintenance therapy with a PD-1 antibody during the stable phase of the disease (defined as no further tumor shrinkage for at least two consecutive assessments based on RECIST v1.1 criteria);
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  • At least one measurable or non-measurable but evaluable lesion according to RECIST version 1.1;
  • Adequate organ function;
  • Female or male patients of childbearing potential must agree to use highly effective contraceptive measures throughout the study period;
  • Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study requirements as specified in the visit schedule.

Exclusion Criteria:

  • Patients who are ineligible for standard anti-tumor therapy according to routine clinical practice;
  • Prior treatment with anti-PD-1/PD-L1 immunotherapy;
  • Concurrent enrollment in another clinical study;
  • Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
  • Receipt of systemic corticosteroids or other immunosuppressive therapy within 2 weeks prior to the first dose of study drug;
  • Receipt of any live vaccine within 4 weeks prior to the first dose of study drug, or planned receipt of live vaccine during the study period;
  • Presence of brainstem, leptomeningeal, spinal cord metastasis, or spinal cord compression;
  • Presence of uncontrolled concomitant diseases, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, etc.;
  • History of severe gastrointestinal ulcer, gastrointestinal perforation, fistula or obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose, or other gastrointestinal diseases that, in the investigator's opinion, may predispose to bleeding or perforation;
  • Presence of severe uncontrolled cardiovascular disease;
  • Interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis) requiring corticosteroid therapy, or current ILD/non-infectious pneumonitis;
  • Concomitant pulmonary disease resulting in clinically severe impairment of respiratory function;
  • Chronic autoimmune disease or inflammatory disease requiring systemic therapy or receiving systemic therapy within 2 years prior to the first dose;
  • Active or history of documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea), intestinal obstruction, or extensive bowel resection;
  • Diagnosis of Gilbert's syndrome;
  • Severe infection within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia;
  • Known active pulmonary tuberculosis;
  • Known active syphilis infection;
  • Known history of immunodeficiency, or positive test for human immunodeficiency virus (HIV) antibody;
  • Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection;
  • Known allergy to any component of any study drug, history of severe allergic reactions (e.g., anaphylactic shock), history of severe hypersensitivity to other monoclonal antibodies or recombinant protein-based substances, or history of severe infusion reactions;
  • Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study period;
  • Any disease, medical condition, organ system dysfunction, or social circumstance (including but not limited to psychiatric illness, substance/alcohol abuse, history of drug abuse, etc.) that, in the investigator's opinion, may interfere with the subject's ability to provide informed consent, adversely affect the subject's cooperation and participation in the study, or confound the interpretation of study results.

Quoted from ClinicalTrials.gov, NCT07637448, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07637448, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07637448